INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 65 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,176,760 | -6.1% | 226,969 | +21.1% | 0.00% | 0.0% |
| Q2 2023 | $7,642,295 | +25.5% | 187,403 | +14.7% | 0.00% | 0.0% |
| Q1 2023 | $6,089,918 | +149.0% | 163,400 | +133.1% | 0.00% | +100.0% |
| Q4 2022 | $2,445,300 | -67.7% | 70,086 | -48.2% | 0.00% | -66.7% |
| Q3 2022 | $7,567,000 | +95.5% | 135,224 | +80.8% | 0.00% | +200.0% |
| Q2 2022 | $3,871,000 | -46.3% | 74,800 | -24.6% | 0.00% | -50.0% |
| Q1 2022 | $7,205,000 | -52.8% | 99,142 | -23.2% | 0.00% | -50.0% |
| Q4 2021 | $15,272,000 | -11.4% | 129,163 | +0.5% | 0.00% | 0.0% |
| Q3 2021 | $17,234,000 | -7.1% | 128,463 | +12.1% | 0.00% | 0.0% |
| Q2 2021 | $18,550,000 | +83.6% | 114,564 | -9.0% | 0.00% | +100.0% |
| Q1 2021 | $10,105,000 | +20.0% | 125,915 | -18.6% | 0.00% | 0.0% |
| Q4 2020 | $8,419,000 | +536.4% | 154,761 | +132.4% | 0.00% | – |
| Q3 2020 | $1,323,000 | -43.0% | 66,588 | -39.7% | 0.00% | -100.0% |
| Q2 2020 | $2,320,000 | +134.8% | 110,375 | +36.7% | 0.00% | – |
| Q1 2020 | $988,000 | +8.9% | 80,727 | +30.5% | 0.00% | – |
| Q4 2019 | $907,000 | +23.1% | 61,870 | +12.1% | 0.00% | – |
| Q3 2019 | $737,000 | -13.8% | 55,186 | +5.7% | 0.00% | – |
| Q2 2019 | $855,000 | +8.0% | 52,214 | +12.5% | 0.00% | – |
| Q1 2019 | $792,000 | +71.4% | 46,412 | +37.1% | 0.00% | – |
| Q4 2018 | $462,000 | -74.3% | 33,852 | -46.0% | 0.00% | -100.0% |
| Q3 2018 | $1,796,000 | -8.0% | 62,746 | -12.1% | 0.00% | 0.0% |
| Q2 2018 | $1,952,000 | +17.3% | 71,373 | -9.6% | 0.00% | – |
| Q1 2018 | $1,664,000 | +149.1% | 78,958 | +127.1% | 0.00% | – |
| Q4 2017 | $668,000 | +61.0% | 34,767 | +108.0% | 0.00% | – |
| Q3 2017 | $415,000 | -14.1% | 16,717 | -44.7% | 0.00% | – |
| Q2 2017 | $483,000 | +213.6% | 30,215 | +176.1% | 0.00% | – |
| Q1 2017 | $154,000 | +266.7% | 10,945 | +231.7% | 0.00% | – |
| Q4 2016 | $42,000 | +2.4% | 3,300 | +37.5% | 0.00% | – |
| Q3 2016 | $41,000 | -19.6% | 2,400 | 0.0% | 0.00% | – |
| Q2 2016 | $51,000 | – | 2,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |